Odanacatib, An Investigational Cathepsin K Inhibitor, Reduced Markers Of Bone Turnove
 

Merck & Co., Inc, Whitehouse Station, NJ, USA, which operates in many countries as Merck Sharp & Dohme or MSD, announced results of a new study in which its investigational selective cathepsin K inhibitor odanacatib reduced measures of bone turnover (breakdown and rebuilding of bone) in women with breast cancer that has spread to the bones (bone metastases). Study results were presented today during an oral session at the VII International Meeting on Cancer Induced Bone Disease.

More...